Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. BioArctic AB (publ)
  6. News
  7. Summary
    BIOA B   SE0010323311

BIOARCTIC AB (PUBL)

(BIOA B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BioArctic Develops New Antibody Treatment for ALS

11/15/2021 | 07:16am EST

BioArctic AB (publ) gave an update on the company's development project ND3014. For the first time, it was announced that the project aims to develop selective antibody treatments targeting TDP-43, a protein that is believed to play a crucial role in the development of the rare neurodegenerative disease ALS. ALS (amyotrophic lateral sclerosis) is a devastating neurodegenerative disease that affects the body's ability to control muscle activity. TDP-43 (TAR DNA-binding protein 43) is a key protein that impacts the disease development. When this protein is misfolded, it creates toxic aggregates, causing a stepwise degeneration of motor neurons in the brain, the brain stem, and the spinal cord. Aggregates of TDP-43 in the central nervous system is a common clinical finding in ALS, found in most cases of patients in studies. Misfolded TDP-43 has also been shown in many patients with frontotemporal dementia and Alzheimer's disease. The aim of BioArctic's development of selective antibody treatments toward TDP-43 is to decrease the levels of the toxic TDP-43 aggregates in nerve cells, and thus achieve a disease-modifying effect.


ę S&P Capital IQ 2021
All news about BIOARCTIC AB (PUBL)
2021BioArctic Secures US FDA's Fast Track For Early Alzheimer's Disease Treatment
MT
2021Lecanemab granted Fast Track designation by the FDA
AQ
2021Bioarctic AB Announces Lecanemab Granted Fast Track Designation by the FDA
CI
2021BioArctic Develops New Antibody Treatment for ALS
CI
2021BioArctic develops new antibody treatment for ALS
AQ
2021New data on lecanemab presented at the CTAD Alzheimer conference
AQ
2021DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer's disea..
AQ
2021Bioarctic AB Announces DIAN-TU Selects Lecanemab for Clinical Trial for Dominantly Inhe..
CI
2021New data published on ABBV-0805 in Neurobiology of Disease
AQ
2021Bioarctic AB Announces New Data Published on Abbv-0805 in Neurobiology of Disease
CI
More news
Financials
Sales 2021 121 M 13,4 M 13,4 M
Net income 2021 -60,3 M -6,68 M -6,68 M
Net cash 2021 904 M 100 M 100 M
P/E ratio 2021 -158x
Yield 2021 -
Capitalization 9 510 M 1 056 M 1 054 M
EV / Sales 2021 71,3x
EV / Sales 2022 13,8x
Nbr of Employees 49
Free-Float -
Chart BIOARCTIC AB (PUBL)
Duration : Period :
BioArctic AB (publ) Technical Analysis Chart | BIOA B | SE0010323311 | MarketScreener
Technical analysis trends BIOARCTIC AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 108,00 SEK
Average target price 237,50 SEK
Spread / Average Target 120%
EPS Revisions
Managers and Directors
Gunilla Christina Osswald President & Chief Executive Officer
Jan P. Mattsson Chief Financial Officer & Vice President-Finance
Wenche Nelly A. Rolfsen Sandsborg Chairman
Christer M÷ller Chief Scientific Officer
Tomas Odergren Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOARCTIC AB (PUBL)-9.40%1 056
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684